(AOF) – Korian’s Board of Directors will propose the appointment of a new independent director, in the person of Philippe Lévêque, former Chief Executive Officer of CARE France, during the Combined General Meeting of June 22, 2022 in order to strengthen its ESG expertise. If this appointment is approved, the Board will then have thirteen members, including seven independent directors from the medical sector, charities, education or finance, as well as two directors representing employees.
AOF – LEARN MORE
Oncology supports laboratory performance
Oncology generated $163 billion in revenue in 2021 (out of an industry total of $613 billion), up 11.9%, according to GlobalData. Its average annual growth has reached 15.4% over the past twenty years. This segment, which is increasingly competitive, is dominated by a few heavyweights such as MSD (Merck & Co. Inc), Roche, BMS
.
L
‘
immuno-oncology, the specialty that has been driving this market for ten years, supports research. GlobalData estimates that this segment could reach 180 billion in 2026. The major players are looking to strengthen themselves in this niche. Pfizer recently acquired Canadian biotech Trillium Therapeutics for $2.3 billion. Following this operation, the American group got hold of two promising molecules in the treatment of blood cancer.